While ICIs such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 have shown remarkable success in prolonging survival in cancers like melanoma and lung cancer, they simultaneously disrupt immune homeostasis, leading to unintended immune activation against healthy tissues. Here, CTLA4 is linked to melanoma.